Literature DB >> 32445698

Metabolic Regulation of the Epigenome Drives Lethal Infantile Ependymoma.

Kulandaimanuvel Antony Michealraj1, Sachin A Kumar2, Leo J Y Kim3, Florence M G Cavalli1, David Przelicki2, John B Wojcik4, Alberto Delaidelli5, Andrea Bajic6, Olivier Saulnier1, Graham MacLeod7, Ravi N Vellanki8, Maria C Vladoiu2, Paul Guilhamon1, Winnie Ong2, John J Y Lee2, Yanqing Jiang1, Borja L Holgado1, Alex Rasnitsyn9, Ahmad A Malik10, Ricky Tsai11, Cory M Richman9, Kyle Juraschka2, Joonas Haapasalo1, Evan Y Wang9, Pasqualino De Antonellis1, Hiromichi Suzuki1, Hamza Farooq1, Polina Balin2, Kaitlin Kharas2, Randy Van Ommeren2, Olga Sirbu9, Avesta Rastan1, Stacey L Krumholtz1, Michelle Ly2, Moloud Ahmadi7, Geneviève Deblois8, Dilakshan Srikanthan2, Betty Luu1, James Loukides1, Xiaochong Wu1, Livia Garzia12, Vijay Ramaswamy13, Evgeny Kanshin14, María Sánchez-Osuna14, Ibrahim El-Hamamy15, Fiona J Coutinho1, Panagiotis Prinos16, Sheila Singh17, Laura K Donovan1, Craig Daniels1, Daniel Schramek10, Mike Tyers14, Samuel Weiss18, Lincoln D Stein15, Mathieu Lupien8, Bradly G Wouters8, Benjamin A Garcia4, Cheryl H Arrowsmith19, Poul H Sorensen5, Stephane Angers20, Nada Jabado21, Peter B Dirks22, Stephen C Mack23, Sameer Agnihotri24, Jeremy N Rich25, Michael D Taylor26.   

Abstract

Posterior fossa A (PFA) ependymomas are lethal malignancies of the hindbrain in infants and toddlers. Lacking highly recurrent somatic mutations, PFA ependymomas are proposed to be epigenetically driven tumors for which model systems are lacking. Here we demonstrate that PFA ependymomas are maintained under hypoxia, associated with restricted availability of specific metabolites to diminish histone methylation, and increase histone demethylation and acetylation at histone 3 lysine 27 (H3K27). PFA ependymomas initiate from a cell lineage in the first trimester of human development that resides in restricted oxygen. Unlike other ependymomas, transient exposure of PFA cells to ambient oxygen induces irreversible cellular toxicity. PFA tumors exhibit a low basal level of H3K27me3, and, paradoxically, inhibition of H3K27 methylation specifically disrupts PFA tumor growth. Targeting metabolism and/or the epigenome presents a unique opportunity for rational therapy for infants with PFA ependymoma.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cancer metabolism; ependymoma; epigenetics; hindbrain development; microenvironment; paediatric cancer

Mesh:

Substances:

Year:  2020        PMID: 32445698     DOI: 10.1016/j.cell.2020.04.047

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   66.850


  29 in total

1.  A Chemical Strategy toward Novel Brain-Penetrant EZH2 Inhibitors.

Authors:  Rui Liang; Daisuke Tomita; Yusuke Sasaki; John Ginn; Mayako Michino; David J Huggins; Leigh Baxt; Stacia Kargman; Maaz Shahid; Kazuyoshi Aso; Mark Duggan; Andrew W Stamford; Elisa DeStanchina; Nigel Liverton; Peter T Meinke; Michael A Foley; Richard E Phillips
Journal:  ACS Med Chem Lett       Date:  2022-02-10       Impact factor: 4.345

2.  Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma.

Authors:  Consuelo Torrini; Trang Thi Thu Nguyen; Chang Shu; Angeliki Mela; Nelson Humala; Aayushi Mahajan; Erin Heather Seeley; Guoan Zhang; Mike-Andrew Westhoff; Georg Karpel-Massler; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin
Journal:  Mol Cell       Date:  2022-08-09       Impact factor: 19.328

3.  Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.

Authors:  Jichang Han; Meng Yu; Yiqin Bai; Jianzhong Yu; Fei Jin; Chen Li; Rong Zeng; Jinghong Peng; Ao Li; Xiaomin Song; Hao Li; Dianqing Wu; Lin Li
Journal:  Cancer Cell       Date:  2020-11-12       Impact factor: 31.743

Review 4.  Metabolic Coordination of Cell Fate by α-Ketoglutarate-Dependent Dioxygenases.

Authors:  Sanjeethan C Baksh; Lydia W S Finley
Journal:  Trends Cell Biol       Date:  2020-10-19       Impact factor: 20.808

5.  The Bidirectional Relationship Between Cancer Epigenetics and Metabolism.

Authors:  Luke T Izzo; Hayley C Affronti; Kathryn E Wellen
Journal:  Annu Rev Cancer Biol       Date:  2020-11-30

6.  H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.

Authors:  Felix Behling; Christina Fodi; Irina Gepfner-Tuma; Kristina Kaltenbach; Mirjam Renovanz; Frank Paulsen; Marco Skardelly; Jürgen Honegger; Marcos Tatagiba; Jens Schittenhelm; Ghazaleh Tabatabai
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

Review 7.  The roles of Polycomb repressive complexes in mammalian development and cancer.

Authors:  Andrea Piunti; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2021-03-15       Impact factor: 94.444

8.  World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology.

Authors:  Erik P Sulman; David D Eisenstat
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

Review 9.  Polycomb repressive complex 2 in the driver's seat of childhood and young adult brain tumours.

Authors:  Brian Krug; Ashot S Harutyunyan; Shriya Deshmukh; Nada Jabado
Journal:  Trends Cell Biol       Date:  2021-06-03       Impact factor: 21.167

10.  Targeting fibroblast growth factor receptors to combat aggressive ependymoma.

Authors:  Walter Berger; Johannes Gojo; Daniela Lötsch; Dominik Kirchhofer; Bernhard Englinger; Li Jiang; Konstantin Okonechnikov; Daniel Senfter; Anna Laemmerer; Lisa Gabler; Christine Pirker; Andrew M Donson; Peter Bannauer; Pia Korbel; Carola N Jaunecker; Jens-Martin Hübner; Lisa Mayr; Sibylle Madlener; Maria T Schmook; Gerda Ricken; Kendra Maaß; Michael Grusch; Klaus Holzmann; Bettina Grasl-Kraupp; Sabine Spiegl-Kreinecker; Jennifer Hsu; Christian Dorfer; Karl Rössler; Amedeo A Azizi; Nicholas K Foreman; Andreas Peyrl; Christine Haberler; Thomas Czech; Irene Slavc; Mariella G Filbin; Kristian W Pajtler; Marcel Kool
Journal:  Acta Neuropathol       Date:  2021-05-27       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.